Sarah Sharp1, Marko Poglitsch2, Peter Zilla1, Neil H Davies3, Edward D Sturrock4. 1. Cardiovascular Research Unit, Division of Cardiothoracic Surgery, University of Cape Town, South Africa. 2. Attoquant Diagnostics GmbH, Campus-Vienna-Biocenter 5, Austria. 3. Cardiovascular Research Unit, Division of Cardiothoracic Surgery, University of Cape Town, South Africa Edward.Sturrock@uct.ac.za. 4. Institute of Infectious Disease and Molecular Medicine, Division of Medical Biochemistry, University of Cape Town, South Africa.
Abstract
INTRODUCTION: The renin-angiotensin system (RAS) is a dynamic network that plays a critical role in blood pressure regulation and fluid and electrolyte homeostasis. Modulators of the RAS, such as angiotensin-converting enzyme (ACE) inhibitors, are widely used to treat hypertension, heart failure and myocardial infarction. METHODS: The effect of ACE inhibitors (lisinopril and C-domain-selective LisW-S) on the constituent peptides of the RAS following myocardial infarction was examined in rats. Ten angiotensin peptides were analysed using a sensitive LC-MS/MS-based assay to examine both the circulating and equilibrium levels of these peptides. RESULTS: Administration of lisinopril or LisW-S caused a significant decrease in Ang 1-8/Ang 1-10 ratios as determined by circulating and equilibrium peptide level analysis. Furthermore, Ang 1-7 levels were elevated by both ACE inhibitors, but only lisinopril decreased the Ang 1-5/Ang 1-7 ratio. This indicates LisW-S C-domain specificity as Ang 1-5 is generated by hydrolysis of Ang 1-7 by the N-domain. Further corroboration of LisW-S C-domain specificity is that only lisinopril increased the circulating levels of the N-domain ACE substrate Ac-SDKP. CONCLUSION: LisW-S is able to effectively block ACE in vivo by C-domain-selective inhibition. The LC-MS/MS-based assay allows the evaluation of the pharmacologic impact of RAS inhibitors in different pathophysiological conditions.
INTRODUCTION: The renin-angiotensin system (RAS) is a dynamic network that plays a critical role in blood pressure regulation and fluid and electrolyte homeostasis. Modulators of the RAS, such as angiotensin-converting enzyme (ACE) inhibitors, are widely used to treat hypertension, heart failure and myocardial infarction. METHODS: The effect of ACE inhibitors (lisinopril and C-domain-selective LisW-S) on the constituent peptides of the RAS following myocardial infarction was examined in rats. Ten angiotensin peptides were analysed using a sensitive LC-MS/MS-based assay to examine both the circulating and equilibrium levels of these peptides. RESULTS: Administration of lisinopril or LisW-S caused a significant decrease in Ang 1-8/Ang 1-10 ratios as determined by circulating and equilibrium peptide level analysis. Furthermore, Ang 1-7 levels were elevated by both ACE inhibitors, but only lisinopril decreased the Ang 1-5/Ang 1-7 ratio. This indicates LisW-S C-domain specificity as Ang 1-5 is generated by hydrolysis of Ang 1-7 by the N-domain. Further corroboration of LisW-S C-domain specificity is that only lisinopril increased the circulating levels of the N-domain ACE substrate Ac-SDKP. CONCLUSION:LisW-S is able to effectively block ACE in vivo by C-domain-selective inhibition. The LC-MS/MS-based assay allows the evaluation of the pharmacologic impact of RAS inhibitors in different pathophysiological conditions.
Authors: Oliver Domenig; Arndt Manzel; Nadja Grobe; Eva Königshausen; Christopher C Kaltenecker; Johannes J Kovarik; Johannes Stegbauer; Susan B Gurley; Dunja van Oyen; Marlies Antlanger; Michael Bader; Daisy Motta-Santos; Robson A Santos; Khalid M Elased; Marcus D Säemann; Ralf A Linker; Marko Poglitsch Journal: Sci Rep Date: 2016-09-21 Impact factor: 4.379
Authors: Lauren B Arendse; A H Jan Danser; Marko Poglitsch; Rhian M Touyz; John C Burnett; Catherine Llorens-Cortes; Mario R Ehlers; Edward D Sturrock Journal: Pharmacol Rev Date: 2019-10 Impact factor: 25.468
Authors: Maria Paz Ocaranza; Jaime A Riquelme; Lorena García; Jorge E Jalil; Mario Chiong; Robson A S Santos; Sergio Lavandero Journal: Nat Rev Cardiol Date: 2019-08-19 Impact factor: 32.419
Authors: Darcy Adin; Clarke Atkins; Oliver Domenig; Teresa DeFrancesco; Bruce Keene; Sandra Tou; Joshua A Stern; Kathryn M Meurs Journal: J Vet Intern Med Date: 2020-02-29 Impact factor: 3.333
Authors: Shalinee Jha; Ulrike Taschler; Oliver Domenig; Marko Poglitsch; Benjamin Bourgeois; Marion Pollheimer; Lisa M Pusch; Grazia Malovan; Saša Frank; Tobias Madl; Karl Gruber; Robert Zimmermann; Peter Macheroux Journal: J Biol Chem Date: 2020-06-16 Impact factor: 5.157
Authors: Rhéure Alves-Lopes; Augusto C Montezano; Karla B Neves; Adam Harvey; Francisco J Rios; Dominik S Skiba; Lauren B Arendse; Tomasz J Guzik; Delyth Graham; Marko Poglitsch; Edward Sturrock; Rhian M Touyz Journal: Hypertension Date: 2021-07-26 Impact factor: 10.190